UBS Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Neutral 50.3%

Neg 0% Neu 50.3% Pos 0%

UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $48.